Leuprorelin Acetate ( DrugBank: Leuprorelin, Acetate )
2 diseases
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
1 | 球脊髄性筋萎縮症 | 7 |
76 | 下垂体性ゴナドトロピン分泌亢進症 | 6 |
1. 球脊髄性筋萎縮症
臨床試験数 : 18 / 薬物数 : 15 - (DrugBank : 8) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 17
Showing 1 to 7 of 7 diseases
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | JPRN-JapicCTI-183981 | 02/11/2017 | 01/06/2018 | Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg All-Case Investigation: Spinal and bulbar muscular atrophy (SBMA) Specified Drug-Use Survey of Leuprorelin AcetateInjection Kit 11.25 mg All-Case Investigation: Spina ... | Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg All-Case Investigation: Spinal and bulbar muscular atrophy (SBMA) Specified Drug-Use Survey of Leuprorelin AcetateInjection Kit 11.25 mg All-Case Investigation: Spina ... | Spinal and bulbar muscular atrophy | Intervention name : Leuprorelin Acetate Dosage And administration of the intervention : Leuprorelin Acetate Injection Kit 11.25 mg, every 12 weeks subcutaneously, for up to at most 8 years. Participants received interventions as part of routine medical care. Intervention name : Leuprorelin Acetate Dosage And administration of the intervention : Leuprorelin A ... | TAKEDA PHARMACEUTICAL COMPANY LTD. | NULL | recruiting | BOTH | 300 | NA | NULL | ||
2 | NCT03555578 (ClinicalTrials.gov) | November 2, 2017 | 1/6/2018 | Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA) Specified Drug-Use Survey of Leuprorelin AcetateInjection Kit 11.25 mg All-Case Investigation: Spina ... | Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA) Specified Drug-Use Survey of Leuprorelin AcetateInjection Kit 11.25 mg All-Case Investigation: Spina ... | Spinal and Bulbar Muscular Atrophy | Drug: Leuprorelin Acetate | Takeda | NULL | Recruiting | N/A | N/A | All | 300 | Japan | |
3 | JPRN-JMA-IIA00080 | 02/2012 | 26/01/2012 | Phase 2 Clinical Trial of Leuprorelin acetate in patients with SBMA (JASMITT-2) | Double-blind Placebo-controlled Phase 2 Clinical Trial of TAP-144-SR (3M) in patients with Spinal and Bulbar Muscular Atrophy (SBMA) Double-blind Placebo-controlled Phase 2 Clinical Trial of TAP-144-SR (3M) in patients with Spinal an ... | Spinal and Bulbar muscular atrophy | Intervention type:DRUG. Intervention1:TAP-144-SR(3M) , Dose form:INJECTION, Route of administration:SUBCUTANEOUS. Control intervention1:placebo, Dose form:INJECTION, Route of administration:SUBCUTANEOUS. Intervention type:DRUG. Intervention1:TAP-144-SR(3M) , Dose form:INJECTION, Route of administration: ... | JASMITT Clinical Trial Office | Jichi med college, Chiba univ., Univ of Tokyo, Tokyo med & dental univ. | Completed | >=30 YEARS | <70 YEARS | Male | 100 | Phase 2 | Japan |
4 | JPRN-UMIN000001455 | 2008/10/01 | 23/10/2008 | Open clinical trial of Leuprorelin Acetate (SR) in patients with Kennedy-Alter-Sung syndrome (KAS) | Open clinical trial of Leuprorelin Acetate (SR) in patients with Kennedy-Alter-Sung syndrome (KAS) - Open clinical trial of Leuprorelin Acetate (SR) in patients with KAS Open clinical trial of Leuprorelin Acetate(SR) in patients with Kennedy-Alter-Sung syndrome (KAS) - ... | Kennedy-Alter-Sung syndrome (KAS) | Leuprorelin acetate (SR) 11.25mg subcutaneous infection per 12 weeks | Department of NeurologyChiba University Graduate School of Medicine | NULL | 20years-old | Not applicable | Male | 10 | Not selected | Japan | |
5 | JPRN-JMA-IIA00111 | 29/08/2007 | 22/02/2013 | Long Term Follow-up Phase III Clinical Trial of Leuprorelin acetate in Patients with SBMA (JASMITT) | Long Term Follow-up Phase III Clinical Trial of TAP-144-SR (3M) in Patients with Spinal and Bulbar Muscular Atrophy (SBMA) Long Term Follow-up Phase III Clinical Trial of TAP-144-SR (3M) in Patients with Spinal and Bulbar M ... | Spinal and Bulbar Muscular Atrophy (SBMA) | Intervention type:DRUG. Intervention1:TAP-144-SR(3M), Dose form:INJECTION, Route of administration:SUBCUTANEOUS, intended dose regimen:every 12 week. Control intervention1:N.A., Dose form:NOT APPLICABLE, Route of administration:NOT APPLICABLE , Intended dose regimen:N.A.. Intervention type:DRUG. Intervention1:TAP-144-SR(3M), Dose form:INJECTION, Route of administration:S ... | Gen Sobue | Ichiro Yabe, Masashi Aoki, Imaharu Nakano, Kazuaki Kanai, Hidehiro Mizusawa, Tomotaka Yamamoto, Kazuko Hasegawa, Masatoyo Nishizawa, Hiroaki Miyajima, Norio Kanda, Kenji Nakajima, Akira Tsujino, Makoto Uchino Ichiro Yabe, Masashi Aoki, Imaharu Nakano, Kazuaki Kanai, Hidehiro Mizusawa, Tomotaka Yamamoto, Kazu ... | Completed | >=30 YEARS | <71 YEARS | Male | 152 | Phase 3 | Japan |
6 | JPRN-JMA-IIA00009 | 13/09/2006 | 24/08/2006 | Phase III Clinical Trial of Leuprorelin acetate in Patients with SBMA (JASMITT) | Double-blind Placebo-controlled Phase III Clinical Trial of TAP-144-SR (3M) in Patients with Spinal and Bulbar Muscular Atrophy (SBMA) Double-blind Placebo-controlled Phase III Clinical Trial of TAP-144-SR (3M) in Patients with Spinal ... | Spinal and Bulbar Muscular Atrophy (SBMA) | Intervention type:DRUG. Intervention1:TAP-144-SR(3M), Dose form:INJECTION, Route of administration:SUBCUTANEOUS. Control intervention1:placebo, Dose form:INJECTION, Route of administration:SUBCUTANEOUS. Intervention type:DRUG. Intervention1:TAP-144-SR(3M), Dose form:INJECTION, Route of administration:S ... | JASMITT Clinical Trial Office | Hokkaido University, Tohoku University, Jichi Medical College, Chiba University, University of Tokyo, Tokyo Medical and Dental University, NHO Sagamitara hospital, Niigata University, Hamamatsu Medical college, Kobe University, Tottori University, Nagasaki University, Kumamoto University Hokkaido University, Tohoku University, Jichi Medical College, Chiba University, University of Tokyo ... | Completed | >=30 YEARS | <70 YEARS | Male | 170 | Phase 3 | Japan |
7 | JPRN-UMIN000000474 | 2003/09/01 | 01/09/2006 | Double-blind Placebo-controlled Clinical Trial of Leuprorelin acetate in Patients with Spinal and Bulbar Muscular Atrophy (SBMA) Double-blind Placebo-controlled Clinical Trial of Leuprorelin acetatein Patients with Spinal and Bul ... | Double-blind Placebo-controlled Clinical Trial of Leuprorelin acetate in Patients with Spinal and Bulbar Muscular Atrophy (SBMA) - Clinical Trial of Leuprorelin acetate in Patients with SBMA Double-blind Placebo-controlled Clinical Trial of Leuprorelin acetatein Patients with Spinal and Bul ... | Spinal and bulbar muscular atrophy (SBMA) | Leuprorelin acetate 3.75 mg subcutaneous injection every 4 weeks Placebo subcutaneous injection every 4 weeks Leuprorelin acetate3.75 mg subcutaneous injection every 4 weeks Placebo subcutaneous injection every ... | Department of Neurology, Nagoya University School of Medicine | NULL | Complete: follow-up complete | 30years-old | 70years-old | Male | 40 | Phase 2 | Japan |
76. 下垂体性ゴナドトロピン分泌亢進症
臨床試験数 : 29 / 薬物数 : 44 - (DrugBank : 14) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 15
Showing 1 to 6 of 6 diseases
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05341115 (ClinicalTrials.gov) | March 20, 2023 | 18/4/2022 | A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty | An Open Label, Multicenter, Single-arm and Prospective Study to Assess the Efficacy and Safety of Leuprorelin 3M in the Treatment of Central Precocious Puberty (CPP) An Open Label, Multicenter, Single-arm and Prospective Study to Assess the Efficacy and Safety of Le ... | Central Precocious Puberty | Drug: Leuprorelin Acetate Depot 3M | Takeda | NULL | Not yet recruiting | N/A | 9 Years | All | 80 | Phase 4 | China |
2 | NCT03963752 (ClinicalTrials.gov) | August 15, 2019 | 22/5/2019 | Clinical Trial of Rapid Progressive Central Precocious Puberty With Integrative Chinese and Western Medicine Clinical Trial of Rapid Progressive Central Precocious Puberty With Integrative Chinese and Western ... | Evidence-based Medical Research on the Treatment of Children's Rapid Progressive Central Precocious Puberty With Integrative Chinese and Western Medicine Evidence-based Medical Research on the Treatment of Children's Rapid Progressive Central Precocious ... | Idiopathic Precocious Puberty | Drug: Ziyinxiehuo Granules Herbs;Drug: Megestrol Acetate Tablet;Drug: Leuprorelin Acetate 3.75mg Injection Drug: Ziyinxiehuo Granules Herbs;Drug: Megestrol Acetate Tablet;Drug: Leuprorelin Acetate3.75mg Inje ... | Children's Hospital of Fudan University | NULL | Recruiting | 5 Years | 8 Years | Female | 164 | Phase 4 | China |
3 | NCT03316482 (ClinicalTrials.gov) | June 11, 2015 | 12/10/2017 | Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty Leuprorelin AcetateDPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty ... | A Multicenter, Open, Prospective Study to Evaluate the Safety and Efficacy of Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty A Multicenter, Open, Prospective Study to Evaluate the Safety and Efficacy of Leuprorelin AcetateDPS ... | Central Precocious Puberty | Drug: Leuplin DPS 11.25mg | Jin Soon Hwang | NULL | Completed | 4 Years | 9 Years | All | 58 | Phase 4 | Korea, Republic of |
4 | EUCTR2014-004495-36-Outside-EU/EEA (EUCTR) | 28/11/2014 | A study of Lupron Depot Lupron Depot in treatment of central premature puberty | Study of Lupron Depot in the Treatment of Central Precocious Puberty | Central Precocious Puberty MedDRA version: 17.1;Level: LLT;Classification code 10073186;Term: Central precocious puberty;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19] Central Precocious Puberty MedDRA version: 17.1;Level: LLT;Classification code 10073186;Term: Centra ... | Trade Name: trade name depends on the source of the product INN or Proposed INN: LEUPRORELIN ACETATE Trade Name: trade name depends on the source of the product INN or Proposed INN: LEUPRORELIN ACETATE Trade Name: trade name depends on the source of the product INN or Proposed INN: LEUPRORELIN ACETATE T ... | Abbvie previously known as Abbott | NULL | NA | Female: yes Male: yes | 55 | United States | ||||
5 | EUCTR2014-004494-16-Outside-EU/EEA (EUCTR) | 03/12/2014 | A clinical trial to determine safety and efficacy of Leuprolide Acetate 11.25mg and 30mg in children with central premature puberty A clinical trial to determine safety and efficacy of Leuprolide Acetate 11.25mg and 30mg in children ... | A 36 Month, Multi-Center, Open-Label Extension Study to Evaluate theSafety of Leuprolide Acetate 11.25 mg and 30 mg Formulations inChildren with Central Precocious Puberty A 36 Month, Multi-Center, Open-Label Extension Study to Evaluate theSafety of Leuprolide Acetate 11. ... | Central Precocious Puberty MedDRA version: 17.1;Level: LLT;Classification code 10073186;Term: Central precocious puberty;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19] Central Precocious Puberty MedDRA version: 17.1;Level: LLT;Classification code 10073186;Term: Centra ... | Trade Name: trade name depends on the source of the product INN or Proposed INN: LEUPRORELIN ACETATE Trade Name: trade name depends on the source of the product’ INN or Proposed INN: LEUPRORELIN ACETATE Trade Name: trade name depends on the source of the product INN or Proposed INN: LEUPRORELIN ACETATE T ... | Abbvie previously known as Abbott | NULL | NA | Female: yes Male: yes | 72 | United States;Puerto Rico | ||||
6 | EUCTR2014-004493-42-Outside-EU/EEA (EUCTR) | 03/12/2014 | A clinical trial to determine safety and efficacy of Leuprolide Acetate 11.25mg and 30mg in children with central premature puberty A clinical trial to determine safety and efficacy of Leuprolide Acetate 11.25mg and 30mg in children ... | A Phase 3, Randomized, Multi-Center, Open-Label Study to Evaluate theEfficacy and Safety of Leuprolide Acetate 11.25 and 30 mg Formulationsin Children with Central Precocious Puberty A Phase 3, Randomized, Multi-Center, Open-Label Study to Evaluate theEfficacy and Safety of Leuproli ... | Central Precocious Puberty MedDRA version: 17.1;Level: LLT;Classification code 10073186;Term: Central precocious puberty;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19] Central Precocious Puberty MedDRA version: 17.1;Level: LLT;Classification code 10073186;Term: Centra ... | Trade Name: trade name depends on the source of the product Product Name: Leuprolide acetate depot INN or Proposed INN: LEUPRORELIN ACETATE Trade Name: trade name depends on the source of the product INN or Proposed INN: LEUPRORELIN ACETATE Trade Name: trade name depends on the source of the product Product Name: Leuprolide acetate depot INN ... | Abbvie previously known as Abbott | NULL | NA | Female: yes Male: yes | 80 | Phase 3 | United States;Puerto Rico |